α-MSH (Alpha-Melanocyte-Stimulating Hormone): Complete Research Profile — POMC-Derived Tridecapeptide in Pigmentation, Energy Regulation, and Neuroimmune Research (2026)

# α-MSH (Alpha-Melanocyte-Stimulating Hormone): Complete Research Profile

> Research Use Only. α-MSH is a laboratory research compound. All information presented here is for scientific and educational purposes only. It is not intended for human or animal use, and no information herein constitutes medical advice or clinical guidance.

---

For dosing, reconstitution, and protocol details, see our Melanotan I (Afamelanotide) Dosage Protocol Guide: MC1R Agonist Research, Reconstitution & Photoprotection 2026.

What Is α-MSH?

Alpha-melanocyte-stimulating hormone (α-MSH) is a tridecapeptide (13 amino acids) derived from the pro-opiomelanocortin (POMC) precursor protein. It is one of the most extensively studied neuropeptides in biomedical research, with documented roles in melanogenesis, energy homeostasis, neuroinflammation, and peripheral immune regulation.

As the parent endogenous ligand of the melanocortin receptor family, α-MSH occupies a central position in a signaling network that intersects dermatology, neuroendocrinology, obesity research, and immunology. Its synthetic analogs — including Melanotan II, PT-141 (Bremelanotide), and KPV — have each isolated and amplified specific facets of its biological activity, making the parent peptide itself an indispensable reference point for melanocortin research.

Key identifiers:

• •Full name: Alpha-melanocyte-stimulating hormone
• •Sequence: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂
• •Length: 13 amino acids
• •Molecular weight: ~1,665 Da
• •CAS number: 581-05-5
• •Primary receptors: MC1R, MC3R, MC4R, MC5R

---

Biochemical Profile and Molecular Structure

α-MSH is the N-terminal tridecapeptide (residues 1–13) of ACTH. Its sequence is: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂.

The peptide features two critical post-translational modifications that distinguish it from ACTH₁₋₁₃:

1. N-terminal acetylation at serine (Ser¹)

2. C-terminal amidation at valine (Val¹³)

These modifications are functionally critical — diacetyl-α-MSH exhibits greater potency at MC1R than the mono- or de-acetylated forms, and amidation is required for full receptor binding affinity.

The pharmacophore ("message sequence") for melanocortin receptor activation is the tetrapeptide His-Phe-Arg-Trp (HFRW), located at positions 6–9 of the full ACTH sequence. This core is conserved across all melanocortin peptides (α-MSH, β-MSH, γ-MSH, ACTH) and represents the minimum sequence needed for receptor binding and activation. Synthetic analogs like MT-II and PT-141 are built around this central motif.

---

POMC Processing and α-MSH Biosynthesis

α-MSH is not directly encoded — it is produced through tissue-specific enzymatic cleavage of the POMC precursor.

The POMC Precursor

POMC is a 241-amino-acid precursor protein expressed in corticotroph cells of the anterior pituitary, melanotroph cells of the intermediate pituitary, neurons in the hypothalamic arcuate nucleus, and peripheral tissues including skin keratinocytes, immune cells, and the GI tract.

The prohormone contains three primary domains:

• •N-terminal region: Contains γ-MSH
• •Central region (ACTH): Contains α-MSH at its N-terminus
• •C-terminal region (β-lipotropin): Contains β-MSH and β-endorphin

Tissue-Specific Processing Pathways

POMC processing is orchestrated by prohormone convertases (PC1/3 and PC2) in a tissue-dependent fashion (Bicknell, 2008; PMID 19343278):

In anterior pituitary corticotrophs:

PC1/3 predominates, producing ACTH (1–39) and β-lipotropin. Minimal downstream processing occurs; α-MSH is not the primary product.

In intermediate pituitary melanotrophs and hypothalamic neurons:

Co-expression of PC1/3 and PC2 enables further cleavage of ACTH to produce ACTH₁₋₁₇, followed by carboxypeptidase E (CPE) trimming and α-amidating monooxygenase (PAM) activity to generate desacetyl-α-MSH. An unidentified N-acetyltransferase (NAT) then produces the fully acetylated, biologically potent form — α-MSH₁₋₁₃ (Wardlaw, 2011; PMC3936413).

This multi-enzyme cascade means α-MSH production is highly regulated and tissue-specific — a critical point for researchers modeling melanocortin signaling in different cell types.

Degradation

α-MSH is degraded primarily by prolylcarboxypeptidase (PRCP) and neprilysin (NEP/CD10), which cleave the Val¹³ amide and His-Phe-Arg-Trp core respectively. PRCP activity in the hypothalamus may represent a homeostatic counterbalance to α-MSH's anorectic (appetite-suppressing) effects (Wallingford et al., 2009; PMC4766861).

---

Melanocortin Receptor System

α-MSH signals through five melanocortin receptors (MC1R–MC5R), all GPCRs that primarily couple to Gαs and activate adenylyl cyclase/cAMP pathways. Understanding receptor-selectivity profiles is essential for interpreting research findings.

A pivotal 2021 review in Pigment Cell & Melanoma Research (PMID 33884776) emphasized that the α-MSH/MC1R axis exerts pleiotropic effects far beyond pigmentation — including anti-tumor immunity, oxidative stress protection, and vascular biology — reframing α-MSH as a systemic cytoprotective hormone.

---

Pigmentation and UV Response Research

The role of α-MSH in skin pigmentation is the best-characterized facet of its biology and is directly mediated by MC1R on melanocytes.

The UV-Pigmentation Cascade

UV irradiation damages DNA and activates p53 in keratinocytes, which transcriptionally upregulates POMC. The resultant α-MSH is secreted and acts on MC1R in adjacent melanocytes. This triggers a cAMP/PKA/CREB cascade that upregulates:

• •MITF (microphthalmia-associated transcription factor)
• •Tyrosinase and TYRP1/TYRP2 (melanin biosynthesis enzymes)
• •Melanin production (both eumelanin and phaeomelanin)

Beyond tanning, this pathway is fundamentally a DNA damage response — UV-induced α-MSH signaling promotes nucleotide excision repair (NER) and reduces UV-induced mutagenesis in melanocytes.

MC1R Genetic Variants and Research Implications

MC1R is highly polymorphic. Loss-of-function variants (e.g., R151C, D294H, R160W) shift melanogenesis toward phaeomelanin, reduce DNA repair efficiency, and significantly increase melanoma risk. These variants are common targets in melanoma genetics research and represent a critical bridge between α-MSH biology and cancer biology.

---

Energy Homeostasis and Appetite Regulation Research

α-MSH is a major central regulator of energy balance through its action at MC4R in the paraventricular nucleus (PVN) of the hypothalamus — one of the most therapeutically significant research applications of melanocortin biology.

The Arcuate Nucleus Circuit

POMC-expressing neurons in the hypothalamic arcuate nucleus (ARC) synthesize α-MSH and project to the PVN and other energy-regulating centers. When energy stores are sufficient:

• •Leptin (adipocyte-derived) activates POMC neurons → ↑ α-MSH release → MC4R activation → ↓ food intake, ↑ energy expenditure
• •NPY/AgRP neurons (orexigenic) are simultaneously suppressed

α-MSH is very effective in regulating eating behavior and energy homeostasis, activating MC3R, MC4R, MC5R, and MC1R — all but MC2R (Fatima et al., 2021; PMID 34882941).

MC4R Mutations and Obesity Research

MC4R mutations represent the most common monogenic form of human obesity, affecting approximately 1–6% of severely obese individuals. More than 200 MC4R variants have been identified, many impairing α-MSH-induced signaling.

A 2023 study in JBC (PMID 37040537) characterized unique signaling profiles for obesity-associated MC4R variants, showing that some mutations selectively impair α-MSH-induced CRE-driven transcription while leaving other downstream pathways intact — a finding with significant implications for understanding why some MC4R variants produce more severe metabolic phenotypes than others.

Knockout mouse studies systematically demonstrated that MC4R-null mice develop massive obesity, hyperphagia, and hyperinsulinemia, while MC3R-null mice show increased fat mass without hyperphagia — establishing distinct roles for each receptor in the energy balance circuit (Butler et al., 2000; PMID 12851322).

This entire research trajectory has seeded drug development for setmelanotide, a selective MC4R agonist now approved for rare genetic obesities — demonstrating how α-MSH receptor pharmacology translates from laboratory models to clinical application.

---

Anti-Inflammatory and Immunomodulatory Research

α-MSH is one of the most comprehensively studied anti-inflammatory neuropeptides. Its anti-inflammatory mechanisms operate at multiple levels — central (hypothalamic) and peripheral (local tissue) — making it a uniquely potent modulator of the neuro-immune axis.

Core Mechanisms

Three general mechanisms have been identified (Catania et al., 2004; PMID 15094510):

1. Inhibition of inflammatory mediator production from peripheral immune cells (macrophages, neutrophils, mast cells)

2. Central neurogenic anti-inflammation via hypothalamic melanocortin circuits that modulate peripheral inflammation

3. Local CNS anti-inflammation through direct action in the brain

The molecular key to these effects is NF-κB suppression — α-MSH preserves IκBα, which retains NF-κB in the cytoplasm and prevents transcription of pro-inflammatory genes (Bhardwaj et al., 1996; PMID 9078687).

Cytokine Suppression Profile

In vitro and in vivo research has shown α-MSH inhibits:

• •IL-1β, IL-6, TNF-α (acute inflammation)
• •IL-8 (at high concentrations)
• •Nitric oxide (NO) production from activated macrophages
• •Fever (via hypothalamic prostaglandin antagonism)

Notably, α-MSH is ineffective against LTB4, PAF, and exogenous IL-8-driven inflammation, indicating that its anti-inflammatory scope, while broad, has defined limits (Catania et al., 1993; PMID 1325196).

Central Neurogenic Pathway

A landmark series of studies established that α-MSH injected into the brain markedly reduces peripheral inflammation induced by IL-1β, TNF-α, and other pro-inflammatory mediators — demonstrating that hypothalamic melanocortin circuits exert systemic anti-inflammatory control (Getting et al., 1994; PMID 8127402).

This central pathway operates through the autonomic nervous system and provides a mechanistic framework for understanding how stress states (which upregulate POMC) modulate systemic inflammation.

KPV: The Distilled Anti-Inflammatory Fragment

The tripeptide KPV (Lys-Pro-Val) represents the C-terminal tripeptide of α-MSH and retains significant anti-inflammatory activity with improved blood-brain barrier penetration. KPV research has focused on intestinal inflammation and barrier function, serving as evidence that α-MSH's anti-inflammatory pharmacophore can be isolated and studied independently.

---

Neuroprotection Research

Beyond energy regulation and inflammation, α-MSH has attracted research interest as a neuroprotective agent, particularly in ischemia/reperfusion injury models.

Ischemia and Stroke Models

A 2021 Frontiers in Neurology study (PMID 34586586) demonstrated that α-MSH promotes neurological recovery and repairs cerebral ischemia/reperfusion injury under hyperglycemic (Type 1 diabetic) conditions. The peptide's neuroprotective effects in this model involved:

• •Anti-inflammatory action (reduced pro-inflammatory cytokines at the injury site)
• •Anti-oxidative effects (reduced ROS production)
• •Anti-apoptotic properties (preserved mitochondrial membrane potential)
• •Upregulation of monocarboxylate transporters (enhancing lactate-based neuronal energy metabolism)

These findings suggest α-MSH may act as an endogenous neuroreserve mechanism — limiting collateral damage during acute CNS insults.

Cognitive and Neurological Signaling

α-MSH and ACTH₄₋₁₀ analogs have long been studied for their influence on learning, memory consolidation, and arousal. The peptide's action at MC4R in limbic circuits is implicated in modulating fear extinction, attention, and stress reactivity — overlapping with the research domains of Semax and other ACTH-derived nootropic compounds.

---

Melanoma and Cancer Biology Research

The intersection of α-MSH with melanoma research is multifaceted — the peptide is both an endogenous tumor suppressor signal and a potential ligand for receptor-targeted cancer diagnostics.

MC1R Expression in Melanoma

MC1R is overexpressed in melanoma cells relative to normal melanocytes, creating a receptor density differential that can be exploited for targeted imaging and therapy. Radiolabeled α-MSH analogs (e.g., ⁶⁴Cu-labeled compounds) have been developed as PET imaging agents for MC1R-positive tumors (Miao et al., 2007; doi:10.1021/bc060306g).

Dual Roles in Tumor Biology

A 2023 comprehensive review (PMID 37608347; PMC10463388) examined the paradoxical role of α-MSH/MC1R in melanoma. The findings reflect genuine complexity:

• •Protective roles: α-MSH/MC1R signaling promotes DNA repair via NER, reduces UV-mutagenesis, and can suppress melanoma cell invasion through anti-inflammatory and anti-invasive mechanisms
• •Potential facilitating roles: In established tumors, some evidence suggests MC1R activation may contribute to immune evasion and therapy resistance, though this remains under active investigation

The net balance appears to depend on timing, tumor stage, and the specific MC1R signaling arms engaged — an active area of research.

Anti-Invasive Research in Melanoma Cells

Early in vitro studies demonstrated α-MSH's anti-invasive effects on human melanoma cells — reducing matrix metalloproteinase activity and inhibiting Matrigel invasion through MC1R-cAMP pathways (PMC2394449). These findings underline the peptide's complexity in oncology contexts.

---

α-MSH vs. Related Melanocortin Peptides

Understanding α-MSH requires situating it within the broader melanocortin research landscape. Key distinctions:

α-MSH's broader receptor promiscuity (MC1R/MC3R/MC4R/MC5R) compared to more selective analogs makes it the best model for studying aggregate melanocortin system biology, while its short half-life (minutes in plasma) distinguishes it from the longer-acting, cyclization-stabilized analogs used in pharmacological research.

---

Research Considerations and Stability

Half-Life and Stability

Native α-MSH has a short plasma half-life of approximately 10–20 minutes, primarily limited by C-terminal amide hydrolysis and the PRCP/neprilysin degradation system. This contrasts sharply with synthetic analogs like MT-II (cyclization extends half-life) or depot formulations.

For in vitro research:

• •α-MSH is most stable lyophilized and stored at −20°C or below
• •Reconstituted solutions should be used promptly or aliquoted for freeze-thaw avoidance
• •Peptide stability is significantly reduced at physiological pH above 7.4 and in the presence of serum proteases

Receptor Desensitization Considerations

Prolonged MC1R or MC4R stimulation with α-MSH induces receptor internalization and β-arrestin-mediated desensitization — an important variable in experimental design for studies using continuous infusion or repeated dosing paradigms.

Species Differences

Mouse, rat, and human α-MSH share 100% sequence identity, making rodent models highly translatable for α-MSH mechanism studies. However, MC1R polymorphism patterns differ between species and human populations, which affects pigmentation studies.

---

Current Research Directions (2025–2026)

Active research frontiers include:

1. Oral bioavailability engineering: Development of α-MSH-derived peptidomimetics with improved GI stability for metabolic research applications — adjacent to the broader oral peptide delivery field

2. Biased MC4R agonism: Research into β-arrestin-biased vs. Gαs-biased α-MSH analogs that may separate satiety effects from other MC4R-mediated functions (cardiovascular, erectile)

3. Melanocortin receptor imaging: ⁶⁴Cu- and ⁶⁸Ga-labeled α-MSH analogs continue to advance as PET tracers for MC1R-positive tumors

4. Neuroinflammation models: α-MSH's role in microglia activation and neuroinflammatory resolution is under investigation, with implications for Alzheimer's and Parkinson's disease models

5. Gut-brain axis: MC3R and MC4R in enteric neurons and vagal pathways mediate α-MSH's effects on gut motility and food reward — connecting to GLP-1 and GLP-2 research circuits

---

Summary

α-MSH (Alpha-Melanocyte-Stimulating Hormone) is a 13-amino-acid POMC-derived tridecapeptide and the endogenous prototype ligand for the melanocortin receptor family. Its research significance spans:

• •Melanogenesis and UV photoprotection via MC1R-driven pigmentation and DNA repair in melanocytes
• •Central energy regulation as the primary anorectic neuropeptide at MC4R in the hypothalamic arcuate-to-PVN circuit
• •Anti-inflammatory neuroimmunology through NF-κB suppression and multi-level cytokine modulation
• •Neuroprotection in ischemia/reperfusion models with anti-apoptotic and antioxidant actions
• •Cancer biology as both a potential protective factor (DNA repair) and a receptor-targeting ligand for melanoma diagnostics

α-MSH serves as the research anchor for the entire melanocortin pharmacology field. Its synthetic analogs — Melanotan II, PT-141, and the truncated KPV — each represent deliberate attempts to exploit specific axes of this peptide's broad biological activity. Understanding α-MSH at the molecular level is foundational for interpreting the research literature on any melanocortin compound.

---

References

1. Wardlaw SL. "alpha-Melanocyte stimulating hormone: production and degradation." Peptides. 2011. PMC3936413

2. Maresca V et al. "Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma." Cancers. 2023. PMID 37608347

3. Bohm M, Luger TA. "Alpha-MSH inhibits inflammatory signalling in Schwann cells." Exp Dermatol. 2004. PMID 15094510

4. Catania A et al. "Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH." Immunol Today. 1997. PMID 9078687

5. Getting SJ et al. "Central neurogenic antiinflammatory action of alpha-MSH." Brain Res Bull. 1994. PMID 8127402

6. Bicknell AB. "The tissue-specific processing of pro-opiomelanocortin." J Neuroendocrinol. 2008. PMID 19343278

7. Wallingford N et al. "Prolylcarboxypeptidase regulates food intake and central melanocortin signaling." Biochemistry. 2009. PMC4766861

8. Fatima SS et al. "Melanocortin-4 receptor complexity in energy homeostasis, obesity and drug development strategies." Diabetes Obes Metab. 2022. PMID 34882941

9. Lotta LA et al. "A unique melanocortin-4-receptor signaling profile for obesity-associated constitutively active variants." J Biol Chem. 2023. PMID 37040537

10. Butler AA et al. "Knockout studies defining different roles for melanocortin receptors in energy homeostasis." Ann NY Acad Sci. 2003. PMID 12851322

11. Yaghmaei P et al. "α-MSH promotes neurological recovery in ischemia/reperfusion injury in T1DM." Front Neurol. 2021. PMID 34586586

12. Garcia-Borron JC et al. "The α-MSH/MC1R interaction: A driver of pleiotropic effects beyond pigmentation." Pigment Cell Melanoma Res. 2021. PMID 33884776

13. Miao Y et al. "64Cu-Labeled Alpha-MSH Analog for microPET Imaging of MC1R Expression." Bioconjug Chem. 2007. doi:10.1021/bc060306g

14. Catania A et al. "Alpha-MSH peptides inhibit acute inflammation induced in mice by IL-1β, IL-6, TNF-α and endogenous pyrogen." Eur J Pharmacol. 1993. PMID 1325196

---

This article is intended for research and educational purposes only. α-MSH is a research compound. It is not approved for human or veterinary use. Researchers should handle all peptides in accordance with applicable institutional and regulatory guidelines.